濮阳东方医院妇科做人流手术便宜濮阳东方医院看阳痿评价比较高,濮阳东方医院男科割包皮价格收费透明,濮阳市东方医院地址在哪,濮阳东方医院男科预约挂号,濮阳东方医院妇科几点上班,濮阳东方医院妇科好不好啊,濮阳东方医院妇科做人流手术先进

BEIJING, Aug. 22 (Xinhuanet) -- Researchers have discovered how a human egg captures an incoming sperm for fertilization, paving the way to help couples suffering from infertility, according to media reports on Monday.An international team of researchers found that a sugar chain known as the sialyl-lewis-x sequence (SLeX) makes the outer coat of the egg “sticky,” which has proven to be helpful in binding the egg and the sperm.As a result, this observation has filled in a huge gap in the understanding of fertility and provides hope for ultimately helping couples who currently cannot conceive.Scientists and doctors know that a sperm identifies an egg when proteins on the head of the sperm match and bind to a series of specific sugars in the egg’s outer coating. With a successful match of proteins, the outside surfaces of the sperm and egg then bind together before merging, which is then followed by delivery of sperm’s DNA into egg.To identify this molecules, the researchers used ultra-sensitive mass-spectrometric imaging technology to observe and identify which molecules are most likely to be key in the binding process.They experimented with a range of synthesised sugars in the laboratory and found that it is SLeX that specifically binds sperm to an egg.According to the World Health Organisation, infertility affects about 15 percent of reproductive-aged couples around the world and almost one in every seven couples in Britain has problems conceiving a child for various reasons.

SAN FRANCISCO, Sept. 12 (Xinhua) -- Amazon.com Inc. is talking with book publishers to launch a rental subscription service for digital books, U.S. media reported on Monday.Several publishing executives said they aren't enthusiastic about the idea because it could lower the value of books and it could also strain their relationships with other retailers that sell their books, The Wall Street Journal quotes people familiar with the matter in a report.The Seattle-based company is considering a digital book library featuring old titles, which would be available to Amazon Prime subscribers, who currently pay 79 U.S. dollars a year for access to digital library of movies and TV shows and unlimited two-day shipping, said the report.Amazon would offer book publishers a substantial fee and could limit the amount of books that Amazon Prime customers could read for free every month, the report cited some sources as saying.The online retailing giant makes the popular electronic reader Kindle and is also reported to launch a color touchscreen tablet before October to compete with Apple's iPad and other devices in the increasingly crowded tablet computer market.The proposal is another sign that retailers are looking for more ways to deliver content digitally as customers increasingly read book and watch TV on personal computers, tablets and other electronic devices, said The Wall Street Journal report.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

CANBERRA, June 6 (Xinhua) -- Australian beef is not to blame for a recent outbreak of E.coli in Japan, Meat and Livestock Australia confirmed on Monday.Twenty people have fallen ill in Japan's Toyama prefecture, with 15 of them infected with the O157 strain of E.coli after eating at a popular Korean-style barbecue restaurant chain, Gyukaka, on May 6.The operators of the restaurant chain, REINS International, said they suspected the bacterium might have been carried by beef imported from Australia.After conducting an investigation into the Japanese outbreak, regional manager for Meat and Livestock Australia, Melanie Brock, said testing shows Australian beef was not the source of the outbreak."The Toyama prefecture health authorities have confirmed following a thorough inspection that imported Australian beef was not the source of an incident of E.coli," Brock said in a statement on Monday."The authorities continue to investigate other food consumed by the affected customers."Brock said Australian beef has long been recognized by the Japanese trade and consumers for its strong safety record.Brock added that Australian beef for export to Japan is processed under the veterinary supervision of the Australian Quarantine and Inspection Service, and is recognized internationally as bearing a high hygienic standard.

BEIJING, Aug. 30 (Xinhua) -- China's second moon orbiter, the Chang'e-2, has arrived in outer space about 1.5 million km away from Earth and is now orbiting the second Lagrange Point (L2), where gravity from the sun and Earth balances the orbital motion of a satellite, Chinese scientists said Tuesday.Chang'e-2 entered L2's orbit at 11:27 p.m. last Thursday after spending 77 days traveling away from its previous orbital path around the moon, according to the State Administration of Science, Technology and Industry for National Defence (SASTIND).The SASTIND said that China is now the world's third country or organization to successfully put a spacecraft into orbit around L2, after the European Space Agency (ESA) and the National Aeronautics and Space Administration (NASA) of the United States.The Chang'e-2 orbiter will carry out exploration activities around L2 in the coming year, SASTIND said.There are five so-called "Lagrange Points" about 1.5 million km way from the Earth in the exact opposite direction from the sun. Putting a spacecraft at any of these points allows it to stay in a fixed position relative to the Earth and sun with a minimal amount of energy needed for course correction.The orbiter completed all of its assigned tasks after blasting off on Oct. 1, 2010, according to the SASTIND. Although the orbiter was only supposed to remain in space for six months, the SASTIND decided to assign additional tasks to it, as it still had fuel in its reserve tanks.Traveling into outer space from the moon's orbit was one of the orbiter's most important missions, according to the SASTIND.Before arriving at its current position in outer space, the Chang'e-2 took photos of the northern and southern poles of the moon. It then descended to a lower orbit, approximately 15 km away from the moon's surface, where it captured high-resolution images of the Sinus Iridum, or "Bay of Rainbows," an area where future moon probes may land.The SASTIND is reportedly planning to launch measure and control stations into outer space by the end of the second half of next year. The Chang'e-2 will be used to test the two stations' functionality at that time.China's ambitious three-stage moon mission will include a moon landing, as well as the launch of a moon rover during the second stage, which is scheduled to take place in 2012. During the third phase, another rover will land on the moon and return to Earth with lunar soil and stone samples for scientific research around 2017.China does not currently have a timetable in place for a manned moon landing. It launched its first lunar probe, the Chang'e-1, in October 2007.In 2003, China became the third country after Russia and the United States to send a human into space. Two more manned space missions followed, the most recent of which took place in 2008.0 The Chang'e probes are named after the Chinese legendary goddess of the moon.